

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



corres. 8

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |    |   |
|---|--|----|---|
| (51) International Patent Classification <sup>6</sup> :<br><b>C07K 14/415, C12N 15/29, A01N 65/00</b>   |  | A1 | (11) International Publication Number: <b>WO 95/04754</b><br>(43) International Publication Date: 16 February 1995 (16.02.95)   |
| (21) International Application Number: PCT/GB94/01636<br>(22) International Filing Date: 29 July 1994 (29.07.94)<br>(30) Priority Data:<br>9316158.6 4 August 1993 (04.08.93) GB<br>9317816.8 27 August 1993 (27.08.93) GB<br>(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).<br>(72) Inventors; and<br>(75) Inventors/Applicants (for US only): BROEKAERT, Willem, Frans [BE/BE]; Levoldlaan 18, B-1700 Dilbeek (BE). CAM-MUE, Bruno, Philippe, Angelo [BE/BE]; J.B. Woutersstraat 109A, B-1652 Alsemberg (BE). REES, Sarah, Bronwen [GB/GB]; 32 Micheldever Way, Forest Park, Bracknell, Berkshire RG12 3XX (GB).<br>(74) Agent: ROBERTS, Timothy, Wace; ZENECA Seeds, Intellectual Property Dept., Jealotts Hill Research Station, P.O. Box 3539, Bracknell, Berks RG12 6YD (GB). |  |    | (81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LV, MD, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).<br><br>Published<br>With international search report. |
| (54) Title: ANTIMICROBIAL PROTEINS  |  |    |   |
| (57) Abstract<br><br>Antimicrobial proteins capable of isolation from seeds of <i>Allium</i> show a wide range of antifungal activity and some activity against Gram-positive bacteria. DNA encoding the proteins may be isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease resistance.   |  |    |   |

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                          |    |                                       |    |                          |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria                  | GB | United Kingdom                        | MR | Mauritania               |
| AU | Australia                | GE | Georgia                               | MW | Malawi                   |
| BB | Barbados                 | GN | Guinea                                | NE | Niger                    |
| BE | Belgium                  | GR | Greece                                | NL | Netherlands              |
| BF | Burkina Faso             | HU | Hungary                               | NO | Norway                   |
| BG | Bulgaria                 | IE | Ireland                               | NZ | New Zealand              |
| BJ | Benin                    | IT | Italy                                 | PL | Poland                   |
| BR | Brazil                   | JP | Japan                                 | PT | Portugal                 |
| BY | Belarus                  | KE | Kenya                                 | RO | Romania                  |
| CA | Canada                   | KG | Kyrgyzstan                            | RU | Russian Federation       |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan                    |
| CG | Congo                    | KR | Republic of Korea                     | SE | Sweden                   |
| CH | Switzerland              | KZ | Kazakhstan                            | SI | Slovenia                 |
| CI | Côte d'Ivoire            | LI | Liechtenstein                         | SK | Slovakia                 |
| CM | Cameroon                 | LK | Sri Lanka                             | SN | Senegal                  |
| CN | China                    | LU | Luxembourg                            | TD | Chad                     |
| CS | Czechoslovakia           | LV | Latvia                                | TG | Togo                     |
| CZ | Czech Republic           | MC | Monaco                                | TJ | Tajikistan               |
| DE | Germany                  | MD | Republic of Moldova                   | TT | Trinidad and Tobago      |
| DK | Denmark                  | MG | Madagascar                            | UA | Ukraine                  |
| ES | Spain                    | ML | Mali                                  | US | United States of America |
| FI | Finland                  | MN | Mongolia                              | UZ | Uzbekistan               |
| FR | France                   |    |                                       | VN | Viet Nam                 |
| GA | Gabon                    |    |                                       |    |                          |

### ANTIMICROBIAL PROTEINS

This invention relates to antimicrobial proteins, processes for their manufacture and use, and DNA sequences coding for them.

In this context, antimicrobial proteins are defined as proteins possessing at least one of the following activities: antifungal activity (which may include anti-yeast activity); antibacterial activity. Activity includes a range of antagonistic effects such as partial inhibition or death. Such proteins may be oligomeric or may be single peptide subunits.

Various proteins with antimicrobial activity have been isolated from plant sources, and such proteins are often believed to take part in host defence mechanisms directed against invading or competing micro-organisms. Some of the proteins are well-characterised, and their amino acid sequence may be known. In some cases, the cDNA or gene encoding the protein has also been isolated and sequenced.

To keep out potential invaders, plants produce a wide array of antifungal compounds, either in a constitutive or an inducible manner. Several classes of proteins with antifungal properties have now been identified, including:

chitinases (Schlumbaum A et al, 1986, Nature, 324, 363-367);

beta-1,3-glucanases (Mauch F et al, 1988, Plant Physiol, 88, 936-942);

chitin-binding lectins (Broekaert WF et al, 1989, Science, 245, 1100-1102; Van Parijs J et al,

1991, *Planta*, 183, 258-264);

permatins (including zeamatins) (Roberts WK and Selitrennikoff CP, 1990, *J Gen Microbiol*, 136, 2150-2155; Vigers AJ et al, 1991, *Molec Plant-Microbe Interact*, 4, 315-323; Woloshuk CP et al, 1991, *Plant Cell*, 3, 619-628);

thionins (Bohlmann and Apel, 1991, *Ann Rev Plant Physiol Plant Mol Biol*, 42:227-240);

ribosome-inactivating proteins (Roberts WK and Selitrennikoff CP, 1986, *Biosci Rep*, 6, 19-29; Leah et al, 1991, *J Biol Chem*, 266, 1564-1573; Carrasco et al, 1981, *Eur J Biochem*, 116, 185-189; Vernon et al, 1985, *Arch Biochem Biophys*, 238, 18-29; Stirpe and Barbieri, 1986, *FEBS Lett*, 195, 1-8).

These proteins have gained considerable attention as they could potentially be used as biocontrol agents.

Other groups of antimicrobial proteins with activity against plant pathogenic fungi (and often some antibacterial activity) are capable of isolation from certain plant species. We have previously described the structural and antifungal properties of several such proteins, including:

the small-sized cysteine-rich proteins Mj-AMP1 (antimicrobial protein 1) and Mj-AMP2 occurring in seeds of Mirabilis jalapa (Cammue BPA et al, 1992, *J Biol Chem*, 267:2228-2233; International Application Publication Number WO92/15691 published on 17 September 1992);

Ac-AMP1 and Ac-AMP2 from Amaranthus caudatus seeds (Broekaert WF et al, 1992, *Biochemistry*, 37:4308-4314; International Application Publication Number WO92/21699 published on 10 December 1992);

Ca-AMP1 from Capsicum annuum, Bm-AMP1 from Briza maxima and related proteins found in other

plants including Delphinium, Catapodium, Baptisia and Microsensis species (International Patent Application Publication Number WO94/11511, published 26 May 1994);

Rs-AFP1 (antifungal protein 1) and Rs-AFP2 from seeds of Raphanus sativus (Terras FRG et al, 1992, J Biol Chem, 267:15301-13309) and related proteins such as Bn-AFP1 and Bn-AFP2 from Brassica napus, Br-AFP1 and Br-AFP2 from Brassica rapa, Sa-AFP1 and Sa-AFP2 from Sinapis alba, At-AFP1 from Arabidopsis thaliana, Dm-AMP1 and Dm-AMP2 from Dahlia merckii, Cb-AMP1 and Cb-AMP2 from Cnicus benedictus, Lc-AFP from Lathyrus cicera, Ct-AMP1 and Ct-AMP2 from Clitoria ternatea (International Patent Application Publication Number WO93/05153 published 18 March 1993). These publications are specifically incorporated herein by reference.

These and other plant-derived antimicrobial proteins are useful as fungicides or antibiotics to improve the disease-resistance or disease-tolerance of crops either during the life of the plant or for post-harvest crop protection. The proteins may be extracted from plant tissue or produced by expression within micro-organisms or synthesised. Exposure of a plant pathogen to an antimicrobial protein may be achieved by application of the protein to plant parts using standard agricultural techniques (eg surface spraying). The proteins may also be used to combat fungal or bacterial disease by expression within plant bodies (rather than just at the surface). The antimicrobial protein may be expressed in an endophyte introduced into plant tissue. DNA encoding the antimicrobial proteins (which may be a cDNA clone, a genomic DNA clone or

DNA manufactured using a standard nucleic acid synthesiser) may also be transformed into a plant, and the proteins expressed within transgenic plants. For example, transgenic tobacco expressing a barley ribosome inactivating protein has increased resistance to the fungal pathogen Rhizoctonia solani (Logemann et al, 1992, Biotechnol, 10:305-308); transgenic tobacco expressing a barley  $\alpha$ -thionin has increased resistance to Pseudomonas bacterial pathogens (Carmona et al, 1993, Plant J, 3(3):457-462); transgenic tobacco expressing a bean chitinase has increased resistance to the fungal pathogen Rhizoctonia solani (Broglie et al, 1991, Science, 254:1194-1197).

Another group of plant proteins have recently been linked to a potential role in plant defence. Non-specific lipid transfer proteins (hereinafter referred to as nsLTPs) are a family of proteins of unknown function, which are classified as lipid transfer proteins based on their ability to shuttle phospholipids between membrane vesicles or organelles in vitro. These proteins are able to translocate phospholipids or other apolar compounds between two membrane systems. Non-specific lipid transfer proteins have been isolated from both mono- and dicotyledonous species, including;

Spinacia oleracea (So-nsLTP; Bernhard WR et al, 1990, Plant Physiol, 95:164-170);

Ricinus communis (CB-A, CB-B and CB-C; Takishima K et al, 1988, Eur J Biochem, 190:107-112);

Daucus carota (Dc-nsLTP or EP2; Sterk et al, 1991, Plant Cell, 9:907-921);

Nicotiana tabacum (TobLTP; Masuta C et al,

1992, FEBS Lett; 311: 119-123);

Hordeum vulgare (PAPI, Mundy J and Rogers JC, 1986, Planta, 169: 51-63));

Zea mays (Zm-nsLTP; Tchang F et al, 1988, J Biol Chem, 263:16849-16855).

These proteins were previously thought to play a role in cytoplasmic lipid shuttling between organelles, that is the transport of phospholipids from endoplasmic reticulum to cell and organelle membranes (Arondel V and Kader JC, 1990, Experientia, 46, 579-585). However, recent evidence shows that at least some nsLTPs are located extra-cellularly, making their proposed function in membrane biogenesis unlikely (Sterk P et al, 1991, Plant Cell, 3, 907-921; Thoma S et al, 1993, Plant J, 3:427-436).

We have previously described an antimicrobial protein isolated from radish seeds, designated Rs-nsLTP (Raphanus sativus non-specific lipid transfer protein) because of its homology with non-specific lipid transfer proteins isolated from other plant species (International Patent Application Publication Number WO93/05153 published on 18 March 1993). Rs-nsLTP inhibits the growth of several fungi in vitro and shows 38 to 53% sequence identity with a variety of non-specific lipid transport proteins from other plant sources. We have therefore proposed a model in which nsLTPs play a role in defence against microbial attack (Terras FRG et al, 1992, Plant Physiol, 100:1055-1058).

Molina A et al (1993, FEBS Letters, 316(2):119-122) isolated four homogeneous proteins (CW18, CW20, CW21, CW22) from barley leaves which

inhibited growth of the pathogens Clavibacter michiganensis subsp. sepedonicus, Pseudomonas solanacearum and Fusarium solani. The amino acid sequences of these proteins were homologous to known nsLTPs from plants (32-62% identical positions). A homologous protein (Cw<sub>41</sub>) was purified from maize leaves and also found to have inhibitory properties. Molina et al therefore proposed a defence role for non-specific lipid transfer proteins from plants. International Patent Application Publication Number WO92/20801 (Universidad Politecnica de Madrid; published on 26 November 1992) discusses the antipathogenic activity (particularly antibacterial activity) of phospholipid transfer proteins (particularly the barley proteins CW18, CW20, CW21 AND CW22), antipathogenic compositions containing such proteins, DNA sequences encoding such proteins and transgenic plants expressing such proteins.

We have now identified novel potent antimicrobial proteins with broad spectrum activity against plant pathogenic fungi and with some antibacterial activity.

According to the present invention, there is provided an antimicrobial protein having substantially the amino acid sequence shown in SEQ ID NO 1.

An antimicrobial protein according to the invention is capable of isolation from seeds of the family Alliaceae, in particular from the genus Allium. Such proteins may also be isolated from the seeds of both related and unrelated species, or may be produced or synthesised by any suitable



method.

The invention further provides a DNA sequence encoding a protein according to the invention, and a vector containing said sequence. The DNA may be cloned or transformed into a biological system allowing expression of the encoded protein.

In a further aspect, the invention provides plants transformed with DNA encoding an antimicrobial protein according to the invention.

The invention further provides a process of combating fungi or bacteria whereby they are exposed to the proteins according to the invention.

An antimicrobial protein according to the invention has been isolated from seeds of Allium cepa (onion) and is hereinafter called Ace-AMP1 (Allium cepa - Antimicrobial Protein 1). Ace-AMP1 shows activity against a range of plant pathogenic fungi.

The amino acid sequence of the Ace-AMP1 protein has been determined by direct sequencing of the protein and by translation of the full-length Ace-AMP1 cDNA sequence. Ace-AMP1 has a unique primary structure. Although it is partially homologous to non-specific lipid transfer proteins (nsLTPs) from various plant sources, Ace-AMP1 is distinguished from the nsLTPs in several ways. Ace-AMP1 deviates at 22% of the positions where all known nsLTPs share conserved residues. In contrast to nsLTPs, Ace-AMP1 is extremely rich in arginine (19 arginines in 93 residues; approximately 20% of amino acid content is arginine). As discussed

above, some nsLTPs have shown antimicrobial activity. However, the antimicrobial activity of Ace-AMP1 is considerably stronger than that of nsLTPs (see comparative tests in Example 7). Ace-AMP1 shows a particularly strong antifungal activity and a particularly broad spectrum of antifungal activity. Moreover, the antimicrobial activity of Ace-AMP1 is significantly higher than that of the nsLTPs when assessed in the presence of inorganic cations at physiological concentrations. In addition, Ace-AMP1 appears to have no lipid transfer activity: tests have shown that, in contrast to nsLTPs like those isolated from maize or wheat seeds, Ace-AMP1 was unable to transfer phospholipids from liposomes to mitochondria. As a further distinction, the structure of the cDNA clone encoding Ace-AMP1 has a preproprotein structure whereas cDNA encoding known nsLTPs has a preprotein structure (see Examples 9, 10 and 11).

An antimicrobial protein according to the invention is a protein having antifungal activity and having an amino acid sequence substantially as shown in SEQ ID NO 1. In particular, an antimicrobial protein according to the invention is rich in arginine.

Knowledge of its primary structure enables manufacture of the antimicrobial protein, or parts thereof, by chemical synthesis using a standard peptide synthesiser. It also enables production of DNA constructs encoding the antimicrobial protein. The DNA sequence may be predicted from the known amino acid sequence or the sequence may be isolated from plant-derived DNA libraries.

Oligonucleotide probes may be derived from the known amino acid sequence and used to screen a cDNA library for cDNA clones encoding some or all of the protein. These same oligonucleotide probes or cDNA clones may be used to isolate the actual antimicrobial protein gene(s) by screening genomic DNA libraries. Such genomic clones may include control sequences operating in the plant genome. Thus it is also possible to isolate promoter sequences which may be used to drive expression of the antimicrobial (or other) proteins. These promoters may be particularly responsive to environmental conditions (such as the presence of a fungal pathogen), and may be used to drive expression of any target gene.

The Ace-AMP1 cDNA has been isolated using PCR-based cloning as described in Example 9.

DNA encoding the antimicrobial protein (which may be a cDNA clone, a genomic DNA clone or DNA manufactured using a standard nucleic acid synthesiser) can then be cloned into a biological system which allows expression of the protein or a part of the protein. The DNA may be placed under the control of a constitutive or inducible promoter. Examples of inducible systems include pathogen induced expression and chemical induction. Hence the protein can be produced in a suitable micro-organism or cultured cell, extracted and isolated for use. Suitable micro-organisms include Escherichia coli, Pseudomonas and yeast. Suitable cells include cultured insect cells and cultured mammalian cells. The genetic material can also be cloned into a virus or bacteriophage. The DNA can also be transformed by known methods into any plant

species, so that the antimicrobial protein is expressed within the plant.

Plant cells according to the invention may be transformed with constructs of the invention according to a variety of known methods (Agrobacterium Ti plasmids, electroporation, microinjection, microprojectile gun, etc). The transformed cells may then in suitable cases be regenerated into whole plants in which the new nuclear material is stably incorporated into the genome. Both transformed monocotyledonous and dicotyledonous plants may be obtained in this way.

Examples of genetically modified plants which may be produced include field crops, cereals, fruit and vegetables such as: oilseed rape, canola, sunflower, tobacco, sugarbeet, cotton, soya, maize, wheat, barley, rice, sorghum, tomatoes, mangoes, peaches, apples, pears, strawberries, bananas, melons, potatoes, carrot, lettuce, cabbage, onion.

The antimicrobial proteins of the invention show surprisingly high activity and inhibit the growth of a variety of plant pathogenic fungi at submicromolar doses. The proteins not only show a wide range of antifungal activity but also activity against Gram positive bacteria. The proteins are thus useful as fungicides or antibiotics, for agricultural or pharmaceutical applications. Exposure of a plant pathogen to an antimicrobial protein may be achieved by expression of the protein within a micro-organism (including an endophyte) which is applied to a plant or the soil in which a plant grows. The proteins may also be used to combat fungal or bacterial disease by

application of the protein to plant parts using standard agricultural techniques (eg spraying). An antimicrobial composition may comprise an antimicrobially effective amount of the protein together with an agriculturally acceptable carrier and/or adjuvant customarily used in agricultural protein formulations (including solid or liquid adjuvants, solvents, surfactants, etc). The proteins may also be used to combat fungal or bacterial disease by expression within plant bodies, either during the life of the plant or for post-harvest crop protection. The protein may also be used as a fungicide or anti-bacterial to treat mammalian infections, or for preservation of products susceptible to contamination by micro-organisms (for example, processed food products).

The antimicrobial proteins may be isolated and purified from appropriate seeds, synthesised artificially from their known amino acid sequence, or produced within a suitable micro-organism by expression of recombinant DNA. The proteins may also be expressed within a transgenic plant.

The invention may be further understood by reference to the drawings, in which:

Figure 1 shows the cation exchange chromatogram for Ace-AMP1 and the associated graph of fungal growth inhibition.

Figure 2 shows the HPLC profile of purified Ace-AMP1.

Figure 3 shows the alignment of the amino acid sequences of Ace-AMP1 and various plant non-specific lipid transfer proteins.

Figure 4 shows the sequences of the

Ace-AMP1 cDNA and translated protein.

Figure 5 is a diagram of the vectors pFAJ3033 and pFAJ3034.

The invention may also be further understood by reference to the Sequence Listing, in which:

SEQ ID NOS 1 to 14 refer to the amino acid sequences in Figure 3:

SEQ ID NO 1 is mature Ace-AMP1;  
SEQ ID NO 2 is Rs-nsLTP;  
SEQ ID NO 3 is So-nsLTP;  
SEQ ID NO 4 is EP2;  
SEQ ID NO 5 is TobnsLTP;  
SEQ ID NO 6 is Le-nsLTP;  
SEQ ID NO 7 is CB-A;  
SEQ ID NO 8 is CB-B;  
SEQ ID NO 9 is CB-C;  
SEQ ID NO 10 is PAPI;  
SEQ ID NO 11 is CW18;  
SEQ ID NO 12 is CW21;  
SEQ ID NO 13 is Ta-nsLTP;  
SEQ ID NO 14 is Zm-nsLTP;

SEQ ID NOS 15 to 16 refer to the sequences in Figure 4:

SEQ ID NO 15 is the nucleic acid sequence of the Ace-AMP1 cDNA;

SEQ ID NO 16 is the amino acid sequence of Ace-AMP1 translated from the cDNA sequence;

SEQ ID NOS 17 to 25 refer to the oligonucleotides listed in Table 5;

SEQ ID NO 17 is OWB114;  
SEQ ID NO 18 is OWB116;  
SEQ ID NO 19 is OWB117;  
SEQ ID NO 20 is OWB111;  
SEQ ID NO 21 is OWB132;  
SEQ ID NO 22 is OWB133;

SEQ ID NO 23 is OWB158;

SEQ ID NO 24 is OWB159;

SEQ ID NO 25 is OWB160.

The following Examples illustrate the invention.

#### EXAMPLE 1

##### Antifungal and Antibacterial Activity Assays.

Antifungal activity was measured by microspectrophotometry as previously described (Broekaert, 1990, FEMS Microbiol Lett, 69:55-60). Routinely, tests were performed with 20  $\mu$ l of a (filter-sterilized) test solution and 80  $\mu$ l of a suspension of fungal spores ( $2 \times 10^4$  spores/ml) in either half strength potato dextrose broth (medium A) or half strength potato dextrose broth with  $\text{CaCl}_2$  and KCl added to final concentrations of 1 mM and 50 mM respectively (medium B).

For experiments on the antagonistic effect of cations, a synthetic growth medium was used. The synthetic growth medium consisted of  $\text{K}_2\text{HPO}_4$  (2.5mM),  $\text{MgSO}_4$  (50  $\mu$ M),  $\text{CaCl}_2$  (50  $\mu$ M),  $\text{FeSO}_4$  (5  $\mu$ M),  $\text{CoCl}_2$  (0.1  $\mu$ M),  $\text{CuSO}_4$  (0.1  $\mu$ M),  $\text{Na}_2\text{MoO}_4$  (2  $\mu$ M),  $\text{H}_3\text{BO}_3$  (0.5  $\mu$ M), KI (0.1  $\mu$ M),  $\text{ZnSO}_4$  (0.5  $\mu$ M),  $\text{MnSO}_4$  (0.1  $\mu$ M), glucose (10g/l), asparagine (1g/l), methionine (20 mg/l), myo-inositol (2 mg/l), biotin (0.2 mg/l), thiamine-HCl (1 mg/l), and pyridoxine-HCl (0.2 mg/l).

Unless otherwise stated the test organism was Fusarium culmorum (strain IMI 180420) and incubation was done at 25°C for 48 hours. The antifungal activity of a sample (units per ml) is defined as the total volume of the assay mixture

divided by the volume of the sample in the assay mixture that gives 50 percent growth inhibition (= dilution factor for 50 percent growth inhibition). Percent growth inhibition is defined as 100 times the ratio of the corrected absorbance of the control microculture minus the corrected absorbance of the test microculture over the corrected absorbance at 595 nm of the control microculture. The corrected absorbance values equal the absorbance at 595 nm of the culture measured after 48 hours minus the absorbance at 595 nm measured after 30 min.

Antibacterial activity was measured microspectrophotometrically as follows. Bacteria were pre-cultured overnight in 2% Tryptone at 30°C in a rotary shaker. A soft agarose medium (2% tryptone; 0.5% low melting point agarose) was inoculated with the bacteria to a cell density of  $10^5$  colony forming units/ml). Aliquots (80  $\mu$ l) of the bacterial suspension were added to filter-sterilized samples (20  $\mu$ l) in flat-bottom 96-well microplates and allowed to solidify. The absorbance at 595 nm of the culture was measured with the aid of a microplate reader after 30 minutes and 24 hours of incubation at 28°C. Percent growth inhibition was calculated as described above for the antifungal activity assay.

Antibiotic activity on yeast was determined as for the antibacterial assay, except that the growth medium consisted of half strength potato dextrose broth (Difco) and 0.5% low melting point agarose. Eighty  $\mu$ l of a suspension of yeast cells in the latter medium ( $10^6$  cells/ml) was added to 20  $\mu$ l of the test solution.



## EXAMPLE 2

**Extraction of basic heat-stable proteins from Allium cepa seeds**

One hundred grammes of Allium cepa seeds (from AVEVE, Belgium) were ground in a coffee mill and the resulting meal was extracted for 2 hours at 4°C with 200 ml of an ice-cold extraction buffer containing 10 mM  $\text{NaH}_2\text{PO}_4$ , 15 mM  $\text{Na}_2\text{HPO}_4$ , 100 mM KCl, 2 mM EDTA and 2 mM thiourea. After extraction, the slurry was mixed in a WARING blender and subsequently squeezed through a jam mincer to separate the extract from the solid residue. The resulting extract was clarified by centrifugation (10 min at 5,000 x g). Solid ammonium sulphate was added to the supernatant to obtain 85% relative saturation and the precipitate allowed to form by standing overnight at 4°C. Following centrifugation at 7,000 x g for 30 minutes, the precipitate was redissolved in 100 ml distilled water and dialyzed extensively against distilled water. After dialysis the solution was adjusted to 50 mM  $\text{NH}_4\text{Ac}$  (pH 9) by addition of the ten-fold concentrated buffer and passed over a Q-Sepharose Fast Flow (Pharmacia, Uppsala, Sweden) column (12 x 5 cm) equilibrated in 50 mM  $\text{NH}_4\text{Ac}$  (pH 9). The protein fraction which passed through the column was lyophilised and redissolved in 200 ml 50 mM  $\text{NH}_4\text{Ac}$  (pH 5.5).

This material represents the basic (pI>9) protein fraction of the seeds. This fraction was further purified as described in Example 3.

## EXAMPLE 3

Purification of an antimicrobial protein from  
Allium cepa seeds

The starting material for the isolation of the Allium cepa antimicrobial protein was the basic protein fraction extracted from the mature seeds as in Example 2. Proteins were further purified by cation exchange chromatography of this extract.

Approximately 200 ml of the basic protein fraction was applied to a S-Sepharose High Performance (Pharmacia) column (10 x 1.6 cm) equilibrated in 50 mM  $\text{NH}_4\text{Ac}$ , pH 5.5. The column was eluted at 2.0 ml/min with a linear gradient from 50 mM to 2 M  $\text{NH}_4\text{Ac}$ , pH 5.5 over 180 minutes. The eluate was monitored for protein by online measurement of the absorbance at 280 nm (results shown in the lower panel of Figure 1) and collected in 20 ml fractions. One ml samples from each fraction were dried by lyophilisation, and redissolved in 1 ml of distilled water of which 20  $\mu\text{l}$  was assayed for antifungal activity as described in Example 1 (Results shown in the upper panel of Figure 1) in both medium A and B.

Following chromatography, the extract yielded a broad and complex peak of antifungal activity, composed of at least two active components with different sensitivity to presence of  $\text{CaCl}_2$  and  $\text{KCl}$  in the assay medium (Medium B) and a well-defined active peak eluting at approximately 1.5 M  $\text{NH}_4$ -acetate. The latter peak, being the less antagonised by  $\text{Ca}^{2+}$  and  $\text{K}^+$  could be further purified by reverse-phase HPLC. One ml of this peak fraction was loaded on a PEP-S (porous silica  $\text{C}_2/\text{C}_{18}$ , Pharmacia) column (25 x 0.4 cm)

equilibrated with 0.1% TFA (trifluoroacetic acid). The column was developed at 1 ml/min with a linear gradient of 0.1% TFA to 100% acetonitrile/0.1% TFA over 50 minutes. The eluate was monitored for protein by online measurement of the absorption at 280 nm (results shown in the lower panel of Figure 2). One ml fractions were collected, vacuum dried, and redissolved in 1 ml distilled water of which 20 µl was used in an antifungal assay as described in Example 1 (results shown in Figure 2, upper panel). The first single well-resolved peak of activity was called Ace-AMP1 (Allium cepa - Antimicrobial Protein 1).

#### EXAMPLE 4

##### Molecular structure of the purified antimicrobial protein, Ace-AMP1

The molecular structure of the purified antimicrobial protein was further analysed. Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was performed on precast commercial gels (PhastGel 8-25% from Pharmacia) using a PhastSystem (Pharmacia) electrophoresis apparatus. The sample buffer contained 200 mM Tris-HCl (pH 8.3), 1% (w/v) SDS, mM EDTA, 0.005% bromophenol blue and, unless otherwise stated, 1% (w/v) dithioerythritol (DTE). Proteins were fixed after electrophoresis in 12.5% glutaraldehyde and silver-stained according to Heukeshoven and Dernick (1985, Electrophoresis, 6:103-112). Molecular weight markers run for comparison were: phosphorylase B (97.4 kDa), bovine serum albumin (66.2 kDa), ovalbumin (42.7 kDa), carbonic anhydrase (31.0 kDa), soybean trypsin-inhibition (21.5 kDa) and lysozyme (14.4 kDa).

SDS-PAGE analysis of reduced and unreduced Ace-AMP1 revealed a single band of approximately 10 kDa and 22 kDa, respectively. The molecular weight of about 10 kDa of the reduced Ace-AMP1 could be confirmed by a similar SDS-PAGE on PhastGel High Density (Pharmacia) which allows increased resolution for proteins below 20 kDa. Determination of the molecular mass of native Ace-AMP1 by gel filtration on Superose-12 (Pharmacia) yielded a value of about 7.5 kDa. The SDS-PAGE molecular mass value of 22 kDa for unreduced Ace-AMP1 may be an overestimation due to a relatively low SDS binding capacity of this compact protein.

Determination of covalently bound sugars using the phenol-sulphuric acid method of Dubois et al (1956, Anal Chem, 28:350-356) and D-glucose as a standard, was negative, suggesting that Ace-AMP1 is not glycosylated.

All cysteine residues of Ace-AMP1 appeared to participate in disulphide bonds, as unreduced Ace-AMP1 did not contain free thiol groups. Thiol group determination was done by the dithionitrobenzoic acid method of Ellman, GL (1959; Arch Biochem Biophys, 82:70-74) using 10 ml of protein. Reduced protein samples were prepared by reaction with 10 mM DTT for 1 hour at 45°C followed by extensive dialysis against distilled water.

## EXAMPLE 5

**Amino acid sequencing of Ace-AMP1**

Cysteine residues were modified by S-carboxyamidomethylation as described in Cammue BPA et al, 1992, J Biol Chem, 267:2228-2233. Reagents were removed by HPLC on a Pep-S (porous silica C<sub>2</sub>/C<sub>18</sub>) (Pharmacia) column (25 x 0.4 cm). The S-carboxyamidomethylated proteins were recovered by eluting the column with a linear gradient from 0.1 % trifluoroacetic acid (TFA) to acetonitrile containing 0.1 % TFA. The resulting protein fractions were subjected to amino acid sequence analysis in a 477A Protein Sequence (Applied Biosystems) with on-line detection of phenylthiohydantoin amino acid derivatives in a 120A Analyser (Applied Biosystems).

Initial attempts to sequence Ace-AMP1 showed that the protein was N-terminally blocked. Since deblocking with pyroglutamate amino peptidase (Boehringer, FRG) was unsuccessful, Ace-AMP1 was digested with the endoproteases Arg-C and Asp-N (both of sequencing grade from Boehringer, FRG). Digestion was done according to the manufacturers' instructions on reduced and S-carboxyamidomethylated Ace-AMP1 applying minimal advised enzyme to protein ratios (w/w) and maximal advised incubation times. Digested peptides were subsequently separated by RP-HPLC on a Pep-S (porous silica C<sub>2</sub>/C<sub>18</sub>; Pharmacia) column (25 x 0.4 cm) using a linear elution gradient from 0.1% TFA to acetonitrile containing 0.1% TFA in 100 minutes at 1 ml/minute. Digestion with Arg-C resulted in at least 10 separable peptides, suggesting already a relatively high arginine content of Ace-AMP1. Treatment with Asp-N generated 3 protein fragments.

After sequencing of these peptides the primary structure of Ace-AMP1 was reconstructed with exception of the blocked N-terminal part.

The Ace-AMP1 amino acid sequence was found to be partially homologous with non-specific lipid transfer proteins (nsLTPs) from different plant sources, including: Rs-nsLTP from Raphanus sativus seeds (Terras FRG et al, 1992, Plant Physiology; 100: 1055-1058); So-nsLTP from Spinacia oleraceae leaves (Bernhard WR et al, 1991, Plant Physiology, 95: 164-170); EP2 from Daucus carota zygotic embryos (Sterk P et al, 1991, Plant Cell, 3: 907-921); TobLTP from Nicotiana tabacum flowers (Masuta C et al, 1992, FEBS Lett; 311:119-123); Le-nsLTP from Lycopersicon esculente (Tonnes-Schumann S et al, 1992, Plant Mol Biol, 18:749-757); CB-A, CB-B and CB-C from Ricinus communis seedlings (Takishima K et al, 1988, Eur J Biochem, 190:1070112); PAPI from Hordeum vulgare seeds (Mundy J and Rogers JC, 1986, Planta, 169: 51-63); CW18 and CW21 from Hordeum vulgare leaves (Molina A et al, 1993, FEBS Lett, 316:119-122); Ta-nsLTP from Triticum aestivum (Simorre JP et al, 1991, Biochem, 30:11600-11608); Zm-nsLTP from Zea mays seedlings (Tchang F et al, 1988, J Biol Chem, 263: 16849-16855). A sequence comparison of Ace-AMP1 with these nsLTPs is given in Figure 3. Gaps introduced for optimal alignment are represented by dashes. The first nine N-terminal amino acids are derived from the nucleotide sequence of Ace-AMP1 cDNA (see Example 5).

From a comparison of the nsLTP sequences shown in Figure 3 (all sequences excluding Ace-AMP1), the

following consensus motif can be derived. All eight cysteines are at conserved positions 4, 14, 30, 31, 51, 53, 77 and 93 (numbering as in Figure 3); hydrophobic residues (L, I, A, V, M) or aromatic residues (F, W, Y) appear at positions 2, 7, 11, 17, 18, 34, 37, 41, 54, 61, 64, 69, 73, 82, 85, 87, and 96; prolines are present at positions 25 and 74; basic residues (H, R, K) are conserved at positions 47 and 55; hydroxy residues (S, T) appear at positions 43 and 88; and a conserved aspartic acid occupies position 46. Ace-AMP1 partly corresponds to this consensus motif, but deviates at the following positions: it does not have hydrophobic/aromatic residues at positions 2, 18, 61 and 69; it does not have the conserved aspartic acid, lysine and serine at positions 46, 55 and 88 respectively. Hence, about 22% of the conserved residues in nsLTP proteins are altered in Ace-AMP1. Moreover, Ace-AMP1 distinguishes itself from all other known nsLTP sequences by a much higher arginine content. Ace-AMP1 contains at least 19 arginines whereas the number of arginines in the nsLTP proteins varies from 1 (So-nsLTP) to 6 (Zm-nsLTP).

It is noted that most cysteine-rich antibiotic peptides found in animals, such as defensins (Lehrer RI et al, 1991, Cell, 64:229-230),  $\beta$ -defensins (Selsted ME et al, 1993, J Biol Chem, 268:6641-6648) and bactenecins (Romeo D et al, 1988, J Biol Chem, 263:9573-9575; Gennaro R et al, 1989, Infect immun, 57:3142-3146) are also particularly rich in arginine.

## EXAMPLE 6

## Stability of the protein's antifungal activity

Table 1 summarises the results of further testing of the stability of the antifungal activity of Ace-AMP1.

Tests for antifungal activity were performed with 20  $\mu$ l samples diluted five-fold with growth medium containing Fusarium culmorum spores, according to the assay method given in Example 1. Untreated control samples consisted of the test proteins at 100  $\mu$ g/ml in 10 mM sodium phosphate buffer (pH 7). Heat stability tests were performed by heating aliquots of the test proteins for 10 minutes at different temperatures up to 100°C. For digestions, proteases were added at 400  $\mu$ g/ml and incubated at 37°C for 16 hours.

TABLE 1

Stability of the antifungal activity of Ace-AMP1

| Treatment                | Relative antifungal activity<br>(% of control activity) |
|--------------------------|---|
| Control                  | 100   |
| Heating at 80°C, 10 min  | 100   |
| Heating at 90°C, 10 min  | 100   |
| Heating at 100°C, 10 min | 100   |
| Chymotrypsin digestion   | 80  |
| Pronase E digestion      | 5   |
| Proteinase K digestion   | 60  |
| Trypsin digestion        | 90  |

The antifungal activity of Ace-AMP1 was not affected by heat treatments up to 100°C for 10 minutes. Ace-AMP1 was relatively resistant to treatments with chymotrypsin, trypsin and



proteinase K while digestion with pronase E reduced the activity almost completely.

#### EXAMPLE 7

##### Antifungal potency of Ace-AMP1

The antifungal potency of the purified protein was assessed on different plant pathogenic fungi, using the assay described in Example 1. Growth of fungi, collection and harvest of fungal spores were done as previously described (Broekaert et al, 1990, FEMS Microbiol Lett, 69:55-60). The following fungal strains were used: Alternaria brassicola MUCL 20297, Ascochyta pisi MUCL 30164, Botrytis cinerea MUCL 30158, Colletotrichum lindemuthianum MUCL 9577, Fusarium culmorum IMI 180420, Fusarium oxysporum f.sp. pisii IMI 236441, Fusarium oxysporum f.sp. lycopersici MUCL 909, Nectria haematococca Collection Van Etten 160-2-2, Phoma betae MUCL 9916, Pyrenophora tritici-repentis MUCL 30217, Pyricularia oryzae MUCL 30166. Verticillium dahliae MUCL 6963.

Serial dilutions of the antifungal proteins were applied to the fungi, using a synthetic growth medium for fungi (SMF) (See Example 1) supplemented with (SMF<sup>+</sup>) or without (SMF<sup>-</sup>) CaCl<sub>2</sub> and KCl to final concentrations of 1 mM and 50mM, respectively. The percent growth inhibition was measured by microspectrophotometry. The concentration required for 50% growth inhibition after 48 h of incubation (IC<sub>50</sub> value) was calculated from the dose-reponse curves.

The IC<sub>50</sub> values of Ace-AMP1 on different plant pathogenic fungi are presented in Table 2, where

they are compared with those determined under the same conditions for three nsLTPs, namely Rs-nsLTP (data from Terras et al, 1992, Plant Physiol. 100:1055-1058), Zm-nsLTP and Ta-nsLTP (isolated as described in Simorre et al, 1991, Biochem, 30:11600-11608).

Both in media SMF<sup>-</sup> and SMF<sup>+</sup>, Ace-AMP1 inhibits all twelve tested fungi by 50% at concentrations equal or below 10 µg/ml (corresponding to about 1 µM). Ace-AMP1 is therefore a potent plant antifungal protein exhibiting a broad inhibitory spectrum.

It is surprising that Ace-AMP1 is almost as active in SMF<sup>+</sup> as in SMF<sup>-</sup>. The activity of an antifungal protein in a cation containing medium such as SMF<sup>+</sup> is believed to be of physiological relevance since all plant cell compartments contain relatively high cation concentrations (Terras FRG et al, 1992, J Biol Chem, 267:15301-15309).

The potency of Ace-AMP1 in SMF<sup>+</sup> compares very favourable to other relatively cation-insensitive antifungal proteins such as Rs-AFP2 which inhibits 8 out of 12 fungi listed in Table 2 at concentrations below 10 µg/ml (Terras FG et al, 1992, J Biol Chem, 267:15301-15309). Ace-AMP1 is also much more potent than a recently described nsLTP-like protein from Raphanus sativus, Rs-nsLTP (Terras FRG et al, 1992, Plant Physiol, 100:1055-1058) which is partly homologous to Ace-AMP1 (see Figure 3). Indeed, none of the fungi listed in Table 2 are inhibited by Rs-nsLTP in SMF<sup>+</sup> at concentrations below 100 µg/ml (Terras FRG et al, 1992, Plant Physiol, 100:1055-1058). Moreover,

two nsLTPs isolated from maize and wheat, Zm-nsLTP and Ta-nsLTP respectively, did not inhibit growth of any of the nine fungi tested in SMF+ at concentrations below 200 EMG/ML (see Table 2). The  $IC_{50}$  value on Fusarium solani of nsLTP proteins isolated from barley leaves (including CW18 and CW21, see Figure 3) varied from approximately 25 to 180  $\mu$ g/ml (depending on the isoform) when assessed in potato dextrose broth as a medium (Molina A et al, 1993, FEBS Lett, 316:119-122). However, the activity of these proteins on other fungi and their sensitivity to cations have not been described.

The activity of Ace-AMP1 on Fusarium culmorum in synthetic growth medium supplemented with different cations (assayed as described in Example 1) has been compared directly with the activity of the Ac-AMP1 antimicrobial peptide from Amaranthus caudatus seeds (Broekaert et al, 1992, Biochemistry, 31: 4308-4314) and of  $\beta$ -purothionin from wheat endosperm (another type of plant seed protein with antimicrobial activity; Redman DG and Fischer N, 1969, J Sci Food Agri, 20: 427-432). Table 3 summarises the  $IC_{50}$  values under different conditions. Whereas Ac-AMP1 is very sensitive to the presence of all tested cations, the activities of Ace-AMP1 and  $\beta$ -purothionin seem to be rather cation-stimulated although not by  $Ca^{2+}$ . The antagonistic effect of  $Ca^{2+}$  is, however, much less pronounced on Ace-AMP1 than on the thionin.

TABLE 2  
Antifungal activity of Ace-AMP1, Rs-nsLTP, Zm-nsLTP and Ta-nsLTP  
on different phytopathogenic fungi

| FUNGUS                    | IC <sub>50</sub> (µg/ml) |      |          |       |          |      |          |      |
|---------------------------|--------------------------|------|----------|-------|----------|------|----------|------|
|                           | Ace-AMP1                 |      | Rs-nsLTP |       | Zm-nsLTP |      | Ta-nsLTP |      |
|                           | SMF-                     | SMF+ | SMF-     | SMF+  | SMF-     | SMF+ | SMF-     | SMF+ |
| <u>A brassicola</u>       | 2.5                      | 1.5  | 48       | 500   | >200     | >200 | >200     | >200 |
| <u>A pisi</u>             | 1.0                      | 10.0 | 41       | 700   | >200     | >200 | >200     | >200 |
| <u>B cinerea</u>          | 3.0                      | 7.0  | 45       | 680   | nd       | nd   | nd       | nd   |
| <u>C lindemuthianum</u>   | 1.5                      | 1.5  | 25       | >1000 | >200     | >200 | >200     | >200 |
| <u>F culmorum</u>         | 6.0                      | 10.0 | 20       | 520   | 200      | >200 | >200     | >200 |
| <u>F oxysporum pisi</u>   | 3.5                      | 4.0  | 58       | 900   | 200      | >200 | >200     | >200 |
| <u>F oxysporum</u>        |                          |      |          |       |          |      |          |      |
| <u>lycopersici</u>        | 3.0                      | 10.0 | 54       | >1000 | 200      | >200 | >200     | >200 |
| <u>N haematococca</u>     | 3.5                      | 7.0  | 100      | >1000 | 60       | >200 | >200     | >200 |
| <u>P betae</u>            | 1.5                      | 7.0  | 18       | 750   | 150      | >200 | >200     | >200 |
| <u>P tritici-repentis</u> | 3.0                      | 3.5  | nd       | nd    | nd       | nd   | nd       | nd   |
| <u>P oryzae</u>           | 3.0                      | 7.0  | 10       | >1000 | nd       | nd   | nd       | nd   |
| <u>V dahliae</u>          | 0.25                     | 0.5  | 7        | 135   | 200      | >200 | >200     | >200 |

(nd = not determined)

TABLE 3

Antifungal activity of Ace-AMP1, Ac-AMP1 and  $\beta$ -purothionin on Fusarium culmorum in synthetic medium supplemented with different cations

|                      | IC50 ( $\mu$ g/ml) |           |            |                                     |                        |                        |                        |
|----------------------|--------------------|-----------|------------|-------------------------------------|------------------------|------------------------|------------------------|
|                      | SMF                | +50 mM K+ | +50 mM Na+ | +50 mM NH <sub>4</sub> <sup>+</sup> | +5 mM Mg <sup>2+</sup> | +5 mM Ba <sup>2+</sup> | +5 mM Ca <sup>2+</sup> |
| Ace-AMP1             | 3                  | 2         | 2          | 1.5                                 | 2                      | 2                      | 6                      |
| Ac-AMP1              | 4                  | 100       | 100        | 50                                  | >200                   | >200                   | >200                   |
| $\beta$ -purothionin | 4                  | 2         | 3          | 2                                   | 2                      | 2.5                    | 35                     |

## EXAMPLE 8

**Anti-bacterial and anti-yeast activity of Ace-AMP1**

The purified protein was assessed for its effect on the growth of the following bacteria: Bacillus megaterium ATCC 13632, Sarcina lutea ATCC 9342, Agrobacterium tumefaciens LMG 188, Alcaligenes eutrophus LMG 1195, Azospirillum brasilense ATCC 29145, Erwinia carotovora subsp carotovora LMG2458, Escherichia coli strain HB101, Pseudomonas solanacearum LMG 2293, Pseudomonas syringae pv tabaci LMG 5192 and Xanthomonas campestris pv campestris LMG 582. It was also assessed for its effect on the growth of Saccharomyces cerevisiae strain Sp1. Bioassays were carried out as described in Example 1. The results are summarised in Table 4.

TABLE 4  
Activity of Ace-AMP1, Rs-nsLTP, Zm-nsLTP, Ta-nsLTP  
on bacteria and yeast

| MICROORGANISM         | Ace-AMP1 | IC50 ( $\mu\text{g/ml}$ ) |          |          |
|-----------------------|----------|---------------------------|----------|----------|
|                       |          | Rs-nsLTP                  | Zm-nsLTP | Ta-nsLTP |
| <u>B megaterium</u>   | 0.8      | 20                        | 60       | >200     |
| <u>S lutea</u>        | 8.0      | >200                      | >200     | >200     |
| <u>A tumefaciens</u>  | >200     | nd                        | nd       | nd       |
| <u>A eutrophus</u>    | >200     | nd                        | nd       | nd       |
| <u>A brasilense</u>   | >200     | nd                        | nd       | nd       |
| <u>E carotovoza</u>   | >200     | >200                      | >200     | >200     |
| <u>E coli</u>         | >200     | nd                        | nd       | nd       |
| <u>P solanacearum</u> | >200     | nd                        | nd       | nd       |
| <u>P syringae</u>     | >100     | >200                      | >200     | >200     |
| <u>X campestris</u>   | >100     | >200                      | >200     | >200     |
| <u>S cerevisiae</u>   | >200     | nd                        | nd       | nd       |

nd= not determined

Ace-AMP1 inhibits growth of both Gram positive bacteria tested (B megaterium and S lutea) but has little or no effect on any of the eight different Gram negative bacteria which were tested or on the yeast S cerevisiae. Rs-nsLTP and Zm-nsLTP are only inhibitory to B megaterium, but are at least 10-fold less active on this bacterium than Ace-AMP1. The ns-LTPs isolated from barley leaves (including CW18 and CW21, see Figure 3) have been reported to inhibit growth of the Gram positive bacterium Clavibacter michiganensis subsp sepedonicus and the Gram negative bacterium P solanacearum (Molina et al, 1993, FEBS Lett, 316:119-122).

## EXAMPLE 9

## PCR-based cloning of the 5' and 3' parts of Ace-AMP1 cDNA

Total RNA was extracted from a mixture of immature seeds collected 15, 21 and 30 days post anthesis.

The 3' part of Ace-AMP1 cDNA was cloned as follows. Total RNA (1 µg) was reverse transcribed in a 30 µl reaction mixture containing 12 units of avian myeloblastosis virus reverse transcriptase (Boehringer Mannheim), appropriate buffer constituents (Sambrook et al, 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press) and 10 pmol of a modified oligo-dT primer (primer OWB114, see Table 5) and incubated for 30 min at 52°C. A fraction of the reverse transcription reaction (0.5 µl) was transferred to a 25 µl PCR reaction mixture containing 5 pmol of the antisense primer OWB114, 5 pmol of the sense primer OWB111 (a degenerated primer corresponding to an internal amino acid sequence of Ace-AMP1, namely PRFQNIIP), 5 nmol dNTPs, 0.5 units of Taq polymerase and Taq polymerase buffer constituents (Sambrook et al, 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press). Temperature cycling for PCR was done according to standard conditions (Sambrook et al., 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press) using a primer annealing temperature of 55°C. PCR reaction products were analysed by agarose gel electrophoresis and a band of about 400 bp (that was absent from control PCR reactions containing the same template but only one of both primers) was isolated using a Prep-a-Gene kit (Biorad) according to the manufacturers instructions. The PCR product was digested with

XbaI, subcloned into the plasmid pEMBL18+ (Boehringer Mannheim) and the insert sequenced on an ALF automated sequencer (Pharmacia) using the Autoread sequencing kit (Pharmacia) with fluoresceine-labelled M13 forward and reverse primers.

The 5' part of the Ace-AMP1 cDNA was cloned as follows. Total RNA was reverse transcribed as described above using either OWB114 or OWB133 (an Ace-AMP1 specific primer, derived from the nucleotide sequence of the 3' part of Ace-AMP1 cDNA) as a primer. Excess primer was removed by gel filtration over a Chromaspin + TE-100 (Clontech) column equilibrated in 10 mM Tris, 1 mM EDTA, 300 mM NaCl, 0.05 % (w/v) SDS (pH8). RNA was subsequently removed by alkaline hydrolysis, the ssDNA was ethanol precipitated as described by Delort et al (1989, Nucl Acids Res, 17:6439-6448), and finally redissolved in 10  $\mu$ l distilled water. The 3' end of these ssDNA preparations (corresponding to the 5' end of the mRNA) were ligated to the oligonucleotide OWB116 which was synthesized with a phosphate group at its 5' end (to allow for ligation to the ssDNA) and an amino group at its 3' end (to avoid primer self-ligation). The ssDNA ligation reaction mixture (30  $\mu$ l) contained 5 pmol of primer OWB116, 2.5  $\mu$ l of ssDNA (see above), 10 units of T4 RNA ligase (New England Biolabs) and T4 RNA ligase buffer constituents (Tessier et al, 1986, Anal Biochem, 158:171-178), and incubation was done at 22°C for 16 h. A fraction (0.1  $\mu$ l) of the ssDNA ligation mixture was transferred to a 25  $\mu$ l PCR reaction mixture containing 5 nmol of primer OWB117 (which is partially complementary to OWB116), 5



mmol of dNTPs, 1.25 units of Taq polymerase and Taq polymerase buffer constituents. After 5 PCR cycles with an annealing temperature of 60°C, 25 pmol of an Ace-AMP1-specific primer (OWB132, corresponding to a position on Ace-AMP1 cDNA immediately upstream of that of OW133) was added to the reaction mixture and 30 additional PCR cycles with an annealing temperature of 55°C were carried out. A PCR product of about 400 bp which was not present in single primer PCR controls was gel-purified as described above. The same 400 bp PCR band was obtained irrespective of whether OWB133 or OWB114 were used in the first strand synthesis. This PCR product was BamHI-digested, subcloned into pEMBL18+ and the nucleotide sequence of the insert determined as described above.

By combining the nucleotide sequences of the 5' and 3' parts (which overlapped by 38 nucleotides) a 686 bp sequence was obtained that corresponds to full length Ace-nsLTP cDNA.

Ace-AMP1 cDNA contains a 396 bp open reading frame coding for 132 amino acids, a 36 bp 5' leader sequence and a 3' untranslated region of 232 bp up to the poly (A+) tail (Figure 4). Analysis of the coding region reveals the presence of a putative signal peptide of 27 amino acids. The predicted signal peptide cleavage site (indicated by an arrow in Figure 4) is in agreement with the rules of von Heijne (1986, Nucl Acids Res, 14:4683-4690) and with the observation that most mature plant nsLTPs have a cysteine at positions 4 and a valine at position 7. The amino acid sequence between amino acids 37 and 120 of the coding region (underlined in Figure 4) identical to the amino acid sequence

determined experimentally for mature Ace-AMP1. The cDNA derived coding region predicted that mature Ace-AMP1 has 9 additional amino acids at the N-terminus relative to the sequence determined in Example 5. This sequence could not be determined experimentally due to the presence of a blocked N-terminal amino acid in mature Ace-AMP1. Furthermore, the translation product of Ace-AMP1 mRNA has 12 amino acids at its carboxyl-terminus which are absent from mature Ace-AMP1. This carboxyl-terminal propeptide is rich in hydrophobic and acidic residues, a characteristic feature of carboxyl-terminal propeptides present in the precursors of vacuolar plant proteins (Nakamura and Matsuoka, 1993, Plant Physiol, 101:1-5).

Such carboxyl-terminal propeptides have in a number of cases been demonstrated to be determinants for targetting the protein to the vacuole (Bednarek and Raikhel, 1991, Plant Cell, 3,:1195-1206; Neuhaus et al, 1991, Proc Natl Acad Sci USA, 88:10362-10366). All nsLTP-like proteins have been shown to be translated as preproteins, which deviates from the preproprotein structure found in the case of Ace-AMP1 (Arondel and Kader, 1990, Experientia, 46:579-585; Madrid and von Wettstein, 1991, Plant Physiol Biochem, 29:705-711).

TABLE 5

Oligonucleotides used for Ace-AMP1 cDNA cloning

| <u>Name</u> | <u>Sequence</u>                               |
|-------------|---|
| OWB114      | 5'-CCACTCTAGAGAATTCACCTTTTTTTTTTTTTTTTTTTT-3' |
| OWB116      | 5'-AGAATTCGCATTGCATCGGATCCATGATCGAT-3'        |
| OWB117      | 5'-ATCGATCATGGATCCGATGCAATGC-3'               |
| OWB111      | 5'-AATTCTAGACCNMGNTTYCARAAYATHCC-3'           |
| OWB132      | 5'-ATCGGATCCGAATTCGTGTTGCGACAATCACGAGG-3'     |
| OWB133      | 5'-ATCGGATCCGAATTCAGGACGAACAAAGGTGTTGC-3'     |
| OWB158      | 5'-TAAGGTACCATGGTTCGCGTTGTATC-3'              |
| OWB159      | 5'-TAAGGATCCTTCAGTTAATCCTGCCGCATTGAATTCG-3'   |
| OWB160      | 5'-TAAGGATCCCTTCATTCCTCAGCGTCCAAG-3'          |

The following oligonucleotides have a sense orientation relative to Ace-AMP1 mRNA:

OWB117, OWB111, OWB158. The remaining oligonucleotides (OWB114, OWB116, OWB132, OWB133, OWB159, OWB160) have an antisense orientation relative to Ace-AMP1 mRNA. The position of each oligonucleotide relative to the Ace-AMP1 cDNA nucleotide sequence is as follows:

|        |                            |
|--------|----------------------------|
| OWB114 | poly(A <sup>+</sup> ) tail |
| OWB116 | 5'-end                     |
| OWB117 | 5'end                      |
| OWB111 | 307-326                    |
| OWB132 | 325-344                    |
| OWB133 | 338-354                    |
| OWB158 | 35-53                      |
| OWB159 | 372-396                    |
| OWB160 | 417-437.                   |

Restriction sites in the oligonucleotides are underlined in Table 5. In OWB116, the 5'OH at the 5' end is phosphorylated and the 3'OH at the 3' end is aminated. The sequence of OWB117 is complementary to nucleotides 8-32 of OWB116. In OWB111: N=G,A,T,C; H=A,C,T; M=A,C; Y=C,T; R=A,G.

## EXAMPLE 10

## Construction of an expression vector

Total onion seed RNA was reverse translated using primer OWB114 as described in example 9. Fractions (0.5  $\mu$ l) of the reaction mixture were used in PCR amplification reactions under standard conditions (Sambrook et al, 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press) using either the primer combination OWB158-OWB159 at a primer annealing temperature of 65°C or the primers OWB158-OWB160 at a primer annealing temperature of 55°C. Primer OWB158 introduces a KpnI site immediately upstream of the natural NcoI site of Ace-AMP1 cDNA (which encompasses the start codon), primer OWB159 introduces a stop codon and a BamHI site behind the codon of amino acid 120 (the last amino acid of mature Ace-AMP1), and primer OWB160 introduces a BamHI site behind the natural stop codon of Ace-AMP1. The resulting OWB158-OWB159 and OWB158-OWB160 amplification products were digested with KpnI and BamHI and subcloned into the corresponding sites of plasmid pBluescript II SK- to yield plasmids pAce2 and pAce1, respectively. The inserts were verified by nucleotide sequencing. The inserts of plasmids pAce1 and pAce2 were isolated by digestion with NcoI and SacI and subsequently ligated into the corresponding sites of the expression vector pBI505 (Datla et al, 1993, Plant Science, 94:139-149), thus creating plasmids pAce3 and pAce4, respectively. In the expression vector pAce3, the coding region of Ace-AMP1 is flanked at its 5' end by the strong constitutive promoter of the 35S RNA of cauliflower mosaic virus with a duplicated enhancer element (to allow for high transcriptional activity, Kay et al, 1987, Science, 236:1299-1302) and the 5' leader sequence

of the alfalfa mosaic virus (to allow for high translational activity, Datla et al, 1993, Plant Science, 94:139-149). The coding region of the Ace-AMP1 cDNA is flanked at its 3' end by the polyadenylation sequence of the Agrobacterium tumefaciens nopaline synthase gene (Bevan et al, 1983, Nature, 304:184-187). Vector pAce4 is identical to pAce3 except that the coding region lacks the domain encoding the 12 carboxyl-terminal amino acids of the propeptide.

#### EXAMPLE 11

##### Construction of plant transformation vectors

The expression vectors pAce3 and pAce4 described in example 10 were digested with HindIII and SacI and the fragments containing the Ace-AMP1 expression cassettes were subcloned into the HindIII-SacI digested plant transformation vector pGPTV-KAN (Becker et al, 1992, Plant Mol Biol, 20:1195-1197) yielding plant transformation vectors pFAJ3033 and pFAJ3034, respectively. A schematic representation of these vectors is shown in Figure 5. The symbols used in Figure 5 are as follows:

- RB: right border of T-DNA
- LB: left border of T-DNA
- Tnos: terminator of T-DNA nopaline synthase gene
- CTPP: carboxy-terminal propeptide domain of Ace-AMP1 cDNA
- MP: mature protein domain of Ace-AMP1 cDNA
- SP: signal peptide domain of Ace-AMP1 cDNA
- AMV: alfalfa mosaic virus 5' leader sequence
- Penh35S: promoter of 35S RNA of cauliflower mosaic virus with duplicated enhancer region

Pnos: promoter of T-DNA nopaline synthase gene  
nptII: coding region of neomycin  
phosphotransferase II gene  
Tg7: terminator of T-DNA gene 7

## EXAMPLE 12

## Plant Transformation

The disarmed Agrobacterium tumefaciens strain LBA4404 (pAL4404) (Hoekema et al, 1983, Nature 303, 179-180) is transformed with the transformation vector using the method of de Framond et al (BioTechnology, 1:262-269).

Tobacco transformation is carried out using leaf discs of Nicotiana tabacum Samsun based on the method of Horsch et al (1985, Science, 227:1229-1231) and co-culturing with Agrobacterium strains containing pFAJ3033 or pFAJ3034. Co-cultivation is carried out under selection pressure of 100 µg/ml kanamycin. Transgenic plants are regenerated on media containing 100 µg/ml kanamycin. These transgenic plants may be analysed for expression of the newly introduced genes using standard western blotting techniques. Plants capable of constitutive expression of the introduced genes may be selected and self-pollinated to give seed. F1 seedlings of the transgenic plants may be further analysed for increased resistance to plant pathogens.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: ZENECA Limited
- (B) STREET: PO BOX 6, SHIRE PARK, BESSEMER ROAD
- (C) CITY: WELWYN GARDEN CITY
- (D) STATE: HERTFORDSHIRE
- (E) COUNTRY: UNITED KINGDOM
- (F) POSTAL CODE (ZIP): AL7 1HD
- (G) TELEPHONE: 0707 323400
- (H) TELEFAX: 0707 337454

## (ii) TITLE OF INVENTION: ANTIMICROBIAL PROTEINS

## (iii) NUMBER OF SEQUENCES: 25

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9316158.6
- (B) FILING DATE: 04-AUG-1993

## (vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9317816.8
- (B) FILING DATE: 27-AUG-1993

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 93 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Ace-AMP1

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

Gln Asn Ile Cys Pro Arg Val Asn Arg Ile Val Thr Pro Cys Val Ala  
1                      5                      10                      15

Tyr Gly Leu Gly Arg Ala Pro Ile Ala Pro Cys Cys Arg Ala Leu Asn  
                   20                  25                  30  
 Asp Leu Arg Phe Val Asn Thr Arg Asn Leu Arg Arg Ala Ala Cys Arg  
                   35                  40                  45  
 Cys Leu Val Gly Val Val Asn Arg Asn Pro Gly Leu Arg Arg Asn Pro  
                   50                  55                  60  
 Arg Phe Gln Asn Ile Pro Arg Asp Cys Arg Asn Thr Phe Val Arg Pro  
                   65                  70                  75                  80  
 Phe Trp Trp Arg Pro Arg Ile Gln Cys Gly Arg Ile Asn  
                   85                  90

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 42 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Rs-nsLTP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Ala Leu Ser Cys Gly Thr Val Asn Ser Leu Asn Ala Ala Cys Ile Gly  
 1                  5                  10                  15  
 Tyr Leu Thr Gln Asn Ala Pro Leu Ala Arg Gly Cys Cys Thr Gly Val  
                   20                  25                  30  
 Thr Asn Leu Asn Asn Met Ala Thr Thr Pro  
                   35                  40

## (2) INFORMATION FOR SEQ ID NO: 3:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 91 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: So-nsLTP



## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Gly Ile Thr Cys Gly Met Val Ser Ser Lys Leu Ala Pro Cys Ile Gly  
 1 5 10 15  
 Ile Leu Lys Gly Gly Pro Leu Gly Gly Gly Cys Cys Gly Gly Ile Lys  
 20 25 30  
 Ala Leu Asn Ala Ala Ala Ala Thr Thr Pro Asp Arg Lys Thr Ala Cys  
 35 40 45  
 Asn Cys Leu Lys Ser Ala Ala Asn Ala Ile Lys Gly Ile Asn Tyr Gly  
 50 55 60  
 Lys Ala Ala Gly Leu Pro Gly Met Cys Gly Val His Ile Pro Tyr Ala  
 65 70 75 80  
 Ile Ser Pro Ser Thr Asn Cys Asn Ala Val His  
 85 90

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 94 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: EP2

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Val Leu Thr Cys Gly Gln Val Thr Gly Ala Leu Ala Pro Cys Leu Gly  
 1 5 10 15  
 Tyr Leu Arg Ser Gln Val Asn Val Pro Val Pro Leu Thr Cys Cys Asn  
 20 25 30  
 Val Val Arg Gly Leu Asn Asn Ala Ala Arg Thr Thr Leu Asp Arg Lys  
 35 40 45  
 Thr Ala Cys Gly Cys Leu Lys Gln Thr Ala Asn Ala Val Thr Gly Leu  
 50 55 60  
 Asn Leu Asn Ala Ala Ala Gly Leu Pro Ala Arg Cys Gly Val Asn Ile  
 65 70 75 80  
 Pro Tyr Lys Ile Ser Pro Thr Thr Asp Cys Asn Arg Val Val  
 85 90

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 91 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: TobLTP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

Ala Leu Ser Cys Gly Gln Val Gln Ser Gly Leu Ala Pro Cys Leu Pro  
1 5 10 15  
Tyr Leu Gln Gly Arg Gly Pro Leu Gly Ser Cys Cys Gly Gly Val Lys  
20 25 30  
Gly Leu Leu Gly Ala Ala Lys Ser Leu Ser Asp Arg Lys Thr Ala Cys  
35 40 45  
Ile Cys Leu Lys Ser Ala Ala Asn Ala Ile Lys Gly Ile Asp Met Gly  
50 55 60  
Lys Ala Ala Gly Leu Pro Gly Ala Cys Gly Val Asn Ile Pro Tyr Lys  
65 70 75 80  
Ile Ser Pro Ser Thr Asp Cys Ser Lys Val Gln  
85 90

## (2) INFORMATION FOR SEQ ID NO: 6:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 91 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Le-nsLTP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Ala Leu Thr Cys Gly Gln Val Thr Ala Gly Leu Ala Pro Cys Leu Pro  
1 5 10 15  
Tyr Leu Gln Gly Arg Gly Pro Leu Gly Gly Cys Cys Gly Gly Val Lys

41

```

                20                25                30
Asn Leu Leu Gly Ser Ala Lys Thr Thr Ala Asp Arg Lys Thr Ala Cys
   35                40                45
Thr Cys Leu Lys Ser Ala Ala Asn Ala Ile Lys Gly Ile Asp Leu Asn
   50                55                60
Lys Ala Ala Gly Ile Pro Ser Val Cys Lys Val Asn Ile Pro Tyr Lys
   65                70                75                80
Ile Ser Pro Ser Thr Asp Cys Ser Thr Val Gln
                85                90

```

## (2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 92 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: CB-A

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

```

Val Asp Cys Gly Gln Val Asn Ser Ser Leu Ala Ser Cys Ile Pro Phe
1                5                10                15
Leu Thr Gly Gly Val Ala Ser Pro Ser Ala Ser Cys Cys Ala Gly Val
                20                25                30
Gln Asn Leu Lys Thr Leu Ala Pro Thr Ser Ala Asp Arg Arg Ala Ala
                35                40                45
Cys Glu Cys Ile Lys Ala Ala Ala Arg Phe Pro Thr Ile Lys Gln
                50                55                60
Asp Ala Ala Ser Ser Leu Pro Lys Lys Cys Gly Val Asp Ile Asn Ile
65                70                75                80
Pro Ile Ser Lys Thr Thr Asn Cys Gln Ala Ile Asn
                85                90

```

## (2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 92 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: CB-C

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

```

Val Asn Cys Gly Gln Val Asn Lys Ala Leu Ser Ser Cys Val Pro Phe
1           5           10           15

Leu Thr Gly Phe Asp Thr Thr Pro Ser Leu Thr Cys Cys Ala Gly Val
          20           25           30

Met Leu Leu Lys Arg Leu Ala Pro Thr Val Lys Asp Lys Arg Ile Ala
          35           40           45

Cys Glu Cys Val Lys Thr Ala Ala Arg Tyr Pro Asn Ile Arg Glu
50           55           60

Asp Ala Ala Ser Ser Leu Pro Tyr Lys Cys Gly Val Val Ile Asn Val
65           70           75           80

Pro Ile Ser Lys Thr Thr Asn Cys His Glu Ile Asn
          85           90

```

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 92 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: CB-B

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

```

Ala Val Pro Cys Ser Thr Val Asp Met Lys Ala Ala Ala Cys Val Gly
1           5           10           15

Phe Ala Thr Gly Lys Asp Ser Lys Pro Ser Gln Ala Cys Cys Thr Gly
          20           25           30

Leu Gln Gln Leu Ala Gln Thr Val Lys Thr Val Asp Asp Lys Lys Ala
          35           40           45

Ile Cys Arg Cys Leu Lys Ala Ser Ser Lys Ser Leu Gly Ile Lys Asp

```

50                      55                      60  
 Gln Phe Leu Ser Lys Ile Pro Ala Ala Cys Asn Ile Lys Val Gly Phe  
 65                      70                      75                      80  
 Pro Val Ser Thr Asn Thr Asn Cys Glu Thr Ile His  
                     85                      90

## (2) INFORMATION FOR SEQ ID NO: 10:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 93 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: PAPI

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

Ala Leu Asn Cys Gly Gln Val Asp Ser Lys Met Lys Pro Cys Leu Thr  
 1                      5                      10                      15  
 Tyr Val Gln Gly Gly Pro Gly Gly Pro Ser Gly Leu Cys Cys Asn Gly  
                     20                      25                      30  
 Val Arg Asp Leu His Asn Gln Ala Gln Ser Ser Gly Asp Arg Gln Thr  
                     35                      40                      45  
 Val Cys Asn Cys Leu Lys Gly Ile Ala Arg Gly Ile His Asn Leu Asn  
                     50                      55                      60  
 Leu Asn Asn Ala Ala Ser Ile Pro Ser Lys Cys Asn Val Asn Val Pro  
 65                      70                      75                      80  
 Tyr Thr Ile Ser Pro Asp Ile Asp Cys Ser Arg Ile Tyr  
                     85                      90

## (2) INFORMATION FOR SEQ ID NO: 11:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 90 amino acids  
 (B) TYPE: amino acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

- (vi) ORIGINAL SOURCE:  
 (A) ORGANISM: CW18

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ile | Thr | Cys | Gly | Gln | Val | Ser | Ser | Ala | Leu | Gly | Pro | Cys | Ala | Ala |
| 1   |     |     | 5   |     |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Tyr | Ala | Lys | Gly | Ser | Ser | Thr | Ser | Pro | Ser | Ala | Gly | Cys | Cys | Ser | Gly |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Val | Lys | Arg | Leu | Ala | Gly | Leu | Ala | Arg | Ser | Thr | Ala | Asp | Lys | Gln | Ala |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Thr | Cys | Arg | Cys | Leu | Lys | Ser | Val | Ala | Gly | Ala | Tyr | Asn | Ala | Gly | Arg |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ala | Ala | Gly | Ile | Pro | Ser | Arg | Cys | Gly | Val | Ser | Val | Pro | Tyr | Thr | Ile |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Ser | Ala | Ser | Val | Asp | Cys | Ser | Lys | Ile | His |     |     |     |     |     |     |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     |     |     |

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 90 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(vi) ORIGINAL SOURCE:  
(A) ORGANISM: CW21

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Ile | Ser | Cys | Gly | Gln | Val | Ser | Ser | Ala | Leu | Ser | Pro | Cys | Ile | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |
| Tyr | Ala | Arg | Gly | Asn | Gly | Ala | Lys | Pro | Pro | Ala | Ala | Cys | Cys | Ser | Gly |
|     |     |     | 20  |     |     |     |     | 25  |     |     |     |     | 30  |     |     |
| Tyr | Lys | Arg | Leu | Ala | Gly | Ala | Ala | Gln | Ser | Thr | Ala | Asp | Lys | Gln | Ala |
|     |     |     | 35  |     |     |     | 40  |     |     |     |     | 45  |     |     |     |
| Thr | Cys | Arg | Cys | Ile | Lys | Ser | Ala | Ala | Gly | Gly | Leu | Asn | Ala | Gly | Lys |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |
| Ala | Ala | Gly | Ile | Pro | Ser | Met | Cys | Gly | Val | Ser | Val | Pro | Tyr | Ala | Ile |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |
| Ser | Ala | Ser | Val | Asp | Cys | Ser | Lys | Ile | Arg |     |     |     |     |     |     |

85

90

## (2) INFORMATION FOR SEQ ID NO: 13:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 90 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Ta-nsLTP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

```

Ile Asp Cys Gly His Val Asp Ser Leu Val Arg Pro Cys Leu Ser Tyr
1           5           10           15
Val Gln Gly Gly Pro Gly Pro Ser Gly Gln Cys Cys Asp Gly Val Lys
          20           25           30
Asn Leu His Asn Gln Ala Arg Ser Gln Ser Asp Arg Gln Ser Ala Cys
          35           40           45
Asn Cys Leu Lys Gly Ile Ala Arg Gly Ile His Asn Leu Asn Glu Asp
          50           55           60
Asn Ala Arg Ser Ile Pro Pro Lys Cys Gly Val Asn Leu Pro Tyr Thr
65           70           75           80
Ile Ser Leu Asn Ile Asp Cys Ser Arg Val
          85           90

```

## (2) INFORMATION FOR SEQ ID NO: 14:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 93 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Zm-nsLTP

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

```

Ala Ile Ser Cys Gly Gln Val Ala Ser Ala Ile Ala Pro Cys Ile Ser
1           5           10           15

```

Tyr Ala Arg Gly Gln Gly Ser Gly Pro Ser Ala Gly Cys Cys Ser Gly  
 20 25 30  
 Val Arg Ser Leu Asn Asn Ala Ala Arg Thr Thr Ala Asp Arg Arg Ala  
 35 40 45  
 Ala Cys Asn Cys Leu Lys Asn Ala Ala Ala Gly Val Ser Gly Leu Asn  
 50 55 60  
 Ala Gly Asn Ala Ala Ser Ile Pro Ser Lys Cys Gly Val Ser Ile Pro  
 65 70 75 80  
 Tyr Thr Ile Ser Thr Ser Thr Asp Cys Ser Arg Val Asn  
 85 90

## (2) INFORMATION FOR SEQ ID NO: 15:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 686 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Ace-AMPl

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

|  |     |
|--|-----|
| AACGAAAATT ACGAAATTAC ATCAATATCT CGAGCCATGG TTCGCGTTGT ATCTTTACTT  | 60  |
| GCAGCATCGA CCTTCATACT GTTGATTATG ATAATCAGCA GTCCGTATGC AAATAGTCAG  | 120 |
| AACATATGCC CAAGGGTTAA TCGAATTGTG ACACCCTGTG TGGCCTACGG ACTCGGAAGG  | 180 |
| GCACCAATCG CCCCATGCTG CAGAGCCCTG AACGATCTAC GGTTTGTGAA TACTAGAAAC  | 240 |
| CTACGACGTG CTGCATGCCG CTGCCTCGTA GGGGTAGTGA ACCGGAACCC CGGTCTGAGA  | 300 |
| CGAAACCCTA GATTTCAGAA CATTCTCTCGT GATTGTCGCA ACACCTTTGT TCGTCCCTTC | 360 |
| TGGTGGCGTC CAAGAATTCA ATGCGGCAGG ATTAACCTTA CGGATAAGCT TATATACTTG  | 420 |
| GACGCTGAGG AATGAAGACT AGGCTCTACT GTTATGCACT ATAGTTTATA GTATATATAC  | 480 |
| TAAATAAAAC AGTATGTGCT GTATAATTTG CAATATGGAC TTATTTATAG CAAGTCCTAA  | 540 |
| TGGTGTCTGC TACTTGGGTC CAGCATTGAG CACTATATAG GCACTATATA GGGTACTATG  | 600 |
| GGCTGATTAT GATGTCAACG GCGGTACTTT ATCTTACATA AATAAATAAT GGGTTTATCT  | 660 |



TGCTTGAAAA AAAAAAAAAA AAAAAA

686

## (2) INFORMATION FOR SEQ ID NO: 16:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 132 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Ace-AMP1 (translated)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

```

Met Val Arg Val Val Ser Leu Leu Ala Ala Ser Thr Phe Ile Leu Leu
1           5           10           15

Ile Met Ile Ile Ser Ser Pro Tyr Ala Asn Ser Gln Asn Ile Cys Pro
          20           25           30

Arg Val Asn Arg Ile Val Thr Pro Cys Val Ala Tyr Gly Leu Gly Arg
          35           40           45

Ala Pro Ile Ala Pro Cys Cys Arg Ala Leu Asn Asp Leu Arg Phe Val
          50           55           60

Asn Thr Arg Asn Leu Arg Arg Ala Ala Cys Arg Cys Leu Val Gly Val
          65           70           75           80

Val Asn Arg Asn Pro Gly Leu Arg Arg Asn Pro Arg Phe Gln Asn Ile
          85           90           95

Pro Arg Asp Cys Arg Asn Thr Phe Val Arg Pro Phe Trp Trp Arg Pro
          100          105          110

Arg Ile Gln Cys Gly Arg Ile Asn Leu Thr Asp Lys Leu Ile Tyr Leu
          115          120          125

Asp Ala Glu Glu
          130

```

## (2) INFORMATION FOR SEQ ID NO: 17:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 39 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB114

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

CCACTCTAGA GAATTCACCT TTTTTTTTTT TTTTTTTTTT

39

- (2) INFORMATION FOR SEQ ID NO: 18:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 32 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB116

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

AGAATTCGCA TTGCATCGGA TCCATGATCG AT

32

- (2) INFORMATION FOR SEQ ID NO: 19:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 25 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB117

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ATCGATCATG GATCCGATGC AATGC

25

- (2) INFORMATION FOR SEQ ID NO: 20:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 29 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB111

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

AATTCTAGAC CNMGNTTYCA RAYATHCC

29

- (2) INFORMATION FOR SEQ ID NO: 21:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB132

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

ATCGGATCCG AATTCGTGTT GCGACAATCA CGAGG

35

- (2) INFORMATION FOR SEQ ID NO: 22:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 35 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB133

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

ATCGGATCCG AATTCAGGAC GAACAAAGGT GTTGC

35

- (2) INFORMATION FOR SEQ ID NO: 23:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB158

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

TAAGGTACCA TGGTTCGCGT TGTATC

26

- (2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 37 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB159

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TAAGGATCCT TCAGTTAATC CTGCCGCATT GAATTCG

37

- (2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:  
(A) LENGTH: 30 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA

- (vi) ORIGINAL SOURCE:  
(A) ORGANISM: OWB160

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

TAAGGATCCC TTCATTCTC AGCGTCCAAG

30


## CLAIMS

1. An antimicrobial protein having substantially the amino acid sequence shown in SEQ ID NO 1.
2. An antimicrobial protein as claimed in claim 1 having substantially the amino acid sequence shown in SEQ ID NO 16.
3. An antimicrobial protein as claimed in either claim 1 or claim 2 which is capable of isolation from seeds of the family Alliaceae.
4. An antimicrobial protein as claimed in claim 3 which is capable of isolation from the genus Allium.
5. An antimicrobial protein as claimed in claim 4 which is the protein Ace-AMP1.
6. DNA encoding an antimicrobial protein as claimed in claim 1.
7. DNA as claimed in claim 6 which has substantially the sequence shown in SEQ ID NO 15.
8. A biological system containing DNA as claimed in claim 6.
9. A biological system as claimed in claim 8 which is a micro-organism.
10. A biological system as claimed in claim 8 which is a plant.

11. A process of combating fungi or bacteria comprising exposure of the fungi or bacteria to an antimicrobial protein as claimed in claim 1.

1 / 5

FIG. 1



2 / 5




FIG. 2



FIG. 3.



|          | 10   | 20                                       | 30         | 40 | 50 | 60 | 70 | 80 | 90 |
|----------|--|--|------------|----|----|----|----|----|----|
| Ace-AMP1 | QNICPRVNRIVTPCVAYGLGRA--PIA-PCCRALNDLR-FVNRNLRRACRLVGVNRNPGLRNPRFQNI                           | PRDCRNTFVRPFWRPRIQCGRIN                  |            |    |    |    |    |    |    |
| Rs-nsLTP | ALSCGTVNSLNAACIGYLTQNA--PLARGCCTGVNLNNMA?TTP????????????????????                               |  |            |    |    |    |    |    |    |
| So-nsLTP | GITCGMVSSKLAPCIGILKGG---PLGGGCCGGIKALNAAAATTPDRKTACNCLKSAANA                                   | IKGINYGKAAAG-LPGMC-GVHI-PYAI             | SPSTNCNAVH |    |    |    |    |    |    |
| EP2      | VLTCGQVTGALAPCLGYLRSQVNVPLTCCNVVRGLNNAARTTLDRKTACGCLKQTANAVTGLNLNAAAG-LPARC-GVNI-PYKISPTTDCNRV |  |            |    |    |    |    |    |    |
| TobLTP   | ALSCGQVQSGLAPCLPYLQGRG--PLG-SCCGGVKGLLGAAKSLSDRKTACICLKSAANA                                   | IKGIDMGKAAAG-LPGAC-GVNI-PYKIS            | SPSTDCSKVQ |    |    |    |    |    |    |
| Le-nsLTP | ALTCGQVTAGLAPCLPYLQGRG--PLG-GCCGGVKNLLGSAKTTADRKTACTCLKSAANA                                   | IKGIDLNKAAAG-IPSVK-KVNI-PYKIS            | SPSTDCSTVQ |    |    |    |    |    |    |
| CB-A     | -VDCGQVNSSLASCIPFLTGGVASPSA-SCCAGVQNLKTLAPTSADRRAA   | CECIKAAAARFPTIKQDAASS-LPKKC-GVDI-NIPIS   | KTTCNQAIN  |    |    |    |    |    |    |
| CB-B     | -VNCGQVNAKALSSCVFPLTGFDTPSL-TCCAGVMLLKRLAPTVKDKRIA   | CECVKTAARYPNIREDAASS-LPYKC-GVVI-NVPIS    | KTTCNCHEIN |    |    |    |    |    |    |
| CB-C     | AVPCSTVDMKAAACVGFATGKDSKPSQ-ACCTGLQQLAQTVKTVDDKKA  | ICRCLKASSKSL-GIKDQFLSK-IPAAC-NIKV-GFPV   | STNTNCETIH |    |    |    |    |    |    |
| PAP1     | ALNCGQVDSKMKPCLTYVQGGPGPSG-LCCNGVRDLHNAQSSGDRQTV   | CNCLKGIARGIHNLNLNNAAS-IPSKC-NVNV-PYTIS   | PDIDCSRIY  |    |    |    |    |    |    |
| CW18     | AITCGQVSSALGPCAAYAKGSSTPSA-GCCSGVKRLAGLARSTADKQAT  | CRCIKSVAGAY-NA--GRAAG-IPSRC-GVSV-PYTIS   | ASVDCSKIH  |    |    |    |    |    |    |
| CW21     | AISCGQVSSALSPCISYARGNGAKPPA-ACCSGYKRLAGAAQSTADKQAT   | CRCIKSAAGGL-NA--GKAAG-IPSMC-GVSV-PYAI    | SASVDCSKIR |    |    |    |    |    |    |
| Ta-nsLTP | -IDCGHVDSLVRPCLSYVQGGPG-PSG-QCCDGVKNLHNQARSQSDRQ   | SACNCLKGIARGIHNLNEDNARS-IPPKC-GVNL-PYTIS | LNIDCSRV   |    |    |    |    |    |    |
| Zm-nsLTP | AISCGQVASAIAPCISYARGQSGPSA-GCCSGVRSILNNAARTTADRRAA   | CNCLKNAAGVSGLNAGNAAS-IPSKC-GVSI-PYTIS    | STSTDCSRVN |    |    |    |    |    |    |

FIG. 4

SUBSTITUTE SHEET (RULE 26)

5 / 5

FIG. 5



## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/01636

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07K14/415 C12N15/29 A01N65/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A01N C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages                    | Relevant to claim No. |
|------------|---|-----------------------|
| A          | WO,A,92 15691 (IMPERIAL CHEMICAL INDUSTRIES PLC) 17 September 1992<br>cited in the application<br>--- |                       |
| A          | WO,A,92 20801 (UNIVERSIDAD POLITECNICA DE MADRID) 26 November 1992<br>-----                           |                       |

☐ Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 October 1994

Date of mailing of the international search report

08 -11- 1994

Name and mailing address of the ISA

European Patent Office; P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Hermann, R

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No  
PCT/GB 94/01636

| Patent document<br>cited in search report | Publication<br>date | Patent family<br>member(s) |         | Publication<br>date |
|---|---------------------|----------------------------|---------|---------------------|
| WO-A-9215691                              | 17-09-92            | AU-B-                      | 652430  | 25-08-94            |
|   |                     | AU-A-                      | 1366492 | 06-10-92            |
|   |                     | BR-A-                      | 9205760 | 23-08-94            |
|   |                     | EP-A-                      | 0576483 | 05-01-94            |
|   |                     | JP-T-                      | 6505160 | 16-06-94            |
| -----                                     |                     |                            |         |                     |
| WO-A-9220801                              | 26-11-92            | AU-A-                      | 1750092 | 30-12-92            |
|   |                     | EP-A-                      | 0540709 | 12-05-93            |
|   |                     | JP-T-                      | 5508423 | 25-11-93            |
| -----                                     |                     |                            |         |                     |

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**